Media coverage about Depomed (NASDAQ:DEPO) has trended somewhat positive this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Depomed earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 43.7952746634263 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern’s scoring:

Several equities research analysts have recently commented on the stock. Royal Bank Of Canada set a $9.00 target price on shares of Depomed and gave the stock a “hold” rating in a research report on Thursday. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $9.00 target price on shares of Depomed in a research report on Thursday. BidaskClub raised shares of Depomed from a “sell” rating to a “hold” rating in a research report on Wednesday. ValuEngine raised shares of Depomed from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Finally, Mizuho raised shares of Depomed from a “neutral” rating to a “buy” rating and set a $9.00 target price for the company in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. Depomed presently has an average rating of “Hold” and an average price target of $11.64.

Depomed (NASDAQ:DEPO) opened at $8.17 on Friday. Depomed has a 12-month low of $4.31 and a 12-month high of $21.38. The company has a quick ratio of 0.79, a current ratio of 0.83 and a debt-to-equity ratio of 2.90.

Depomed (NASDAQ:DEPO) last issued its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.02. Depomed had a negative net margin of 27.73% and a negative return on equity of 51.07%. The company had revenue of $95.40 million during the quarter, compared to analysts’ expectations of $99.11 million. During the same period last year, the company posted $0.28 EPS. Depomed’s revenue was down 13.7% on a year-over-year basis. equities analysts forecast that Depomed will post -1.34 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Depomed (DEPO) Given Coverage Optimism Score of 0.17” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at

About Depomed

Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).

Insider Buying and Selling by Quarter for Depomed (NASDAQ:DEPO)

Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.